Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Philips Medical Systems North America Co.

Division of Royal Philips Electronics NV
www.pmsna.com

Latest From Sadra Medical Inc.

Renal Denervation Sparks Device Market Gold Rush

With the recent success of Ardian’s Symplicity Renal Denervation System, drug-resistant hypertension has emerged as something of a device market “gold rush.” Some observers estimate there are now as many as 40 companies developing various device-based therapies for resistant hypertension, including most of the big names in the cardiovascular device arena – Medtronic, St. Jude Medical, Boston Scientific, Johnson & Johnson, and Covidien PLC – along with a number of start-ups, all of which are racing to stake a claim in this highly promising market. Only time will tell which companies will be successful – even Medtronic, the first player, has yet to complete its sham-controlled US trial. But the technology’s early promise, along with the sheer size of the opportunity and the acute unmet need, clearly have peaked the interest of investors, manufacturers, and physicians alike, all of whom are chasing after what one participant has called “the next biggest thing in cardiology.”

Medical Device Innovation

Start-Up News, May 2012

This month we profile Transcatheter Technologies, which is developing a repositionable TAVI implant, and Cutting Edge Spine, which has created a family of interbody spacers for spinal repair.

Medical Device Innovation

Transcatheter Technologies GMBH

A major limitation of existing transcatheter aortic heart valves is that they are unable to be repositioned once implanted. For these devices, the valve is mounted in a metal stent that contains a balloon, which is inflated once the valve is placed. The valve is then anchored to the heart wall. Transcatheter Technologies GMBH believes its fully repositionable Trinity valve will solve this shortcoming. Once Trinity is initially placed, cardiac surgeons or interventionalists can evaluate the valve function to determine whether the valve needs to be repositioned, retrieved or kept in the same position. Moreover, it allows for a controlled positioning, by slowly opening the valve stent, for a likely first-attempt correct placement.

Medical Device

As TAVI Advances, Adjunctive Devices Multiply

As researchers work to more fully understand the risks and durability of transcatheter aortic heart valve implantation (TAVI) procedures, device innovators are already attempting to engineer solutions to some of the more obvious areas of unmet need.

As researchers work to more fully understand the risks and durability of transcatheter aortic heart valve implantation (TAVI) procedures, device innovators are already attempting to engineer solutions to some of the more obvious areas of unmet need.

Medical Device
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Royal Philips Electronics NV
  • Senior Management
  • Daniel S Woloshen, VP & General Counsel
    Carl Reilly, VP, Service, COO
  • Contact Info
  • Philips Medical Systems North America Co.
    Phone: (425) 487-7000
    22100 Bothell Everett Highway
    P.O. Box 3003
    Bothell, WA 98041-3003
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register